The German registry for treatment exit options for non-infectious uveitis (TOFU)- description and baseline characteristics of first patients

HEINZ Carsten





Non-infectious non-anterior uveitis may cause severe ocular complications leading to loss of visual function and blindness. Being a chronic disease, most cases need long-term immunosuppression using DMARDs. Initiating therapy is often included in international and national treatment guidelines, but no reliable recommendations exist on when and how to reduce /discontinue treatment once disease is quiescent.


This registry is an observational, non-commercial, and non-interventional study and targets patients who are ≥18 years of age with non-infectious uveitis of the posterior segment or retinal vasculitis.


Data are entered prospectively at 28 study sites in Germany and one in Austria through a web-based interface into electronic case report forms (eCRF) implemented in the electronic data capture software REDCap (Version 9, Vanderbilt University, USA). Collected data include ophthalmological, general medical history and patient-reported outcomes (PROs) as well as ophthalmological imaging data at selected sites. Up to now 526 patients could be included. The majority had intermediate (39%), followed by posterior (29%) and Panuveitis (26%). Retinal vasculitis was present in 7% of patients.


The evidence generated by TOFU will support standardizing management of non-infectious uveitis, will improve treatment outcomes, reduce unwanted side effects, treatment costs, sick days off work as well as increase quality of life of the affected patients.

Back to Calendar

IUSG Office, Rue de L'Industrie 24, B-1040 Brussels, Belgium - VAT: BE 725 942 753